Recent Research Analysts’ Ratings Changes for Novartis (NVS)

Several brokerages have updated their recommendations and price targets on shares of Novartis (NYSE: NVS) in the last few weeks:

• 9/21/2026 – Novartis had its “sell” rating reaffirmed by The Goldman Sachs Group, Inc..
• 9/17/2026 – Novartis had its “neutral” rating reaffirmed by UBS Group AG.
• 9/17/2026 – Novartis had its “neutral” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 9/11/2026 – Novartis had its price target lowered by Berenberg Bank from $147.00 to $130.00. They now have a “hold” rating on the stock.
• 9/10/2026 – Novartis was upgraded by HSBC Holdings plc from “reduce” to “hold”. They now have a $136.00 price target on the stock, up from $123.00.
• 9/10/2026 – Novartis was upgraded by HSBC Holdings plc from “reduce” to “hold”. They now have a $136.00 price target on the stock, up from $123.00.
• 9/8/2026 – Novartis was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”.
• 9/8/2026 – Novartis is now covered by Royal Bank Of Canada. They set a “sector perform” rating on the stock.
• 9/8/2026 – Novartis had its “buy” rating reaffirmed by Bank of America Corporation.
• 8/9/2026 – Novartis had its “buy” rating reaffirmed by JPMorgan Chase & Co..

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.

Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.